autologous ET1402L1-CART cells / Eureka Therap - LARVOL DELTA

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer (Businesswire) - "Eureka Therapeutics, Inc...announced the publication of a study in Nature’s Scientific Reports entitled 'Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma'. The study was led by Dr. Cheng Liu, President and Chief Executive Officer of Eureka, Dr. Brian M. Baker and Dr. Moumita Dasgupta of the University of Notre Dame, and Dr. Chang Liu of The First Affiliated Hospital of Xi’an Jiaotong University....In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein. Unlike natural TCRs, the TCRm antibody interfaced with the AFP/HLA-A*02 complex by engaging the AFP peptide along its entire length, contacting most of the amino acids and interacting rigidly with the target complex."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=3; Terminated; Sponsor: Aeon Therapeutics (Shanghai) Co., Ltd.; N=18 ➔ 3; Trial completion date: Sep 2019 ➔ Jan 2019; Recruiting ➔ Terminated; Trial primary completion date: Sep 2019 ➔ Jan 2019; Will study new T-cell construct for the same indication

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination